

✓ VOLUME E 9b / Part 2

HETARENES IV

SIX-MEMBERED AND LARGER HETERO-RINGS WITH MAXIMUM UNSATURATION

Editor

Ernst Schaumann

Clausthal/Germany

Authors

D. Kikelj

Ljubljana / Slovenia

N. Ramzaeva

Osnabrück / Germany

H. Rosemeyer

Osnabrück / Germany

F. Seela

Osnabrück / Germany

U. Urleb

Ljubljana / Slovenia



19

98

GEORG THIEME VERLAG STUTTGART · NEW YORK

Contents to all Volumes

Volume E 9 a

- A 6-Ring Systems with Two Heteroatoms**
- 1. 6-Ring Systems with Two O-Atoms**
 - 1.1. 1,2-Dioxins
 - 1.2. 1,4-Dioxins and Annulated Derivatives
- 2. 6-Ring Systems with One O- and One S-Atom**
 - 2.1. 1,2-Oxathiins
 - 2.2. 1,4-Oxathiins and Annulated Derivatives
- 3. 6-Ring Systems with One O- and One N-Atom**
 - 3.1. 1,2-(Benz)Oxazines
 - 3.2. 1,2-Oxazinium Salts
 - 3.3. 1(3), 3(1)-(Benz)Oxazinium Salts
 - 3.4. 1,4-(Benz)Oxazines
 - 3.5. Phenoxazines
 - 3.6. Naphtho[1,8-*de*]-1,3-oxazines
- 4. 6-Ring Systems with Two S-Atoms**
 - 4.1. 1,2-Dithiins
 - 4.2. 1,4-Dithiins and Annulated Derivatives
- 5. 6-Ring Systems with Two Different Heteroatoms**
 - 5.1. 1,2-Thiazines
 - 5.2. 2,1-Benzothiazines
 - 5.3. 1,3-Thiazines and 1,3-Thiazinium Salts
 - 5.4. 1,4-Thiazine Systems
 - 5.5. 1,4-Benzothiazines
 - 5.6. Phenothiazines
- 6. Monocyclic (or Annulated) 6-Ring Systems with Two N-Atoms**
 - 6.1. 1,2-Diazines and Annulated Derivatives
 - 6.1.1. Pyridazines
 - 6.1.2. Cinnolines
 - 6.1.3. Phthalazines
 - 6.1.4. Pyridazino[1,2-*a*]pyridazines

Volume E 9b/Part 1

- 6.2. 1,3- and 1,4-Diazines
 - 6.2.1. Pyrimidines
 - 6.2.2. Pyrazines

Volume E 9b/Part 2

- 6.3. Annulated 1,3- and 1,4-Diazines
 - 6.3.1. Quinazolines
 - 6.3.2. Quinoxalines
 - 6.3.3. Phenazines

7. Bicyclic 6-Ring Systems Each with One to Two *N*-Atoms**7.1. Purines****Volume E 9c****7.2. Pyridodiazines****7.2.1. Pyridopyridazines****7.2.2. Pyridopyrimidines****7.2.3. Pyridopyrazines****7.3. Pteridines****7.4. Other Diazinodiazines****B 6-Ring Systems with Three Heteroatoms****1. 6-Ring Systems with Three Different Heteroatoms****1.1. 1,4,2-Dioxazines****1.2. Oxathiazines****1.3. Oxadiazines****1.4. Dithiazines****1.5. Thiadiazines****2. 6-Ring Systems with Three *N*-Atoms****2.1. 1,2,3-Triazines****2.2. 1,2,4-Triazines****2.3. 1,3,5-Triazines****C 6-Ring Systems with More Than Three Heteroatoms****1. 6-Ring Systems with More Than Three *N*-, *O*-, *S*-Atoms****2. 6-Ring Systems with More Than Three *N*-, *S*-Atoms****3. 1,2,3,4-Tetrazines****4. 1,2,3,5-Tetrazines****5. 1,2,4,5-Tetrazines****6. Pentazines****Volume E 9d****D Aromatic 7-Ring Systems****1. (Benz)Oxepins****2. (Benzo)Thiepins****3. Azepines****3.1. Azepines, Cyclopentazepines and Related Systems****3.2. Benz-, Dibenzo- and Tribenzazepines****4. Aromatic 7-Ring Systems with Two or More Heteroatoms****E Aromatic and Heteroaromatic Medium Rings****1. Azocines, Oligoazocines, Heterocines****2. Cyclazines****F Aromatic and Heteroaromatic Large Rings****1. Porphyrins and Related Compounds****2. Phthalocyanines and Related Compounds****Volume E 9e****Compound Index****Author Index**

Table of Contents

Volume E 9b/Part 2

6.3	Annulated 1,3- and 1,4-Diazines	1
6.3.1	Quinazolines	1
	(D. KIKELJ)	
6.3.1.1.	Synthesis	12
6.3.1.1.1.	By Ring-Closure Reactions	12
6.3.1.1.1.1.	From Arenes	12
6.3.1.1.1.1.1.	Fragment N-C-Arene-N-C	12
6.3.1.1.1.1.2.	Fragments C-Arene-N-C and N	20
6.3.1.1.1.1.3.	Fragments C-Arene-N and C-N	26
6.3.1.1.1.1.4.	Fragment N-Arene-C-N-C	40
6.3.1.1.1.1.5.	Fragment C-Arene-N-C-N	43
6.3.1.1.1.1.6.	Fragments N-Arene-C-N and C	46
6.3.1.1.1.1.7.	Fragments Arene-C-N and C-N	54
6.3.1.1.1.1.8.	Fragment Arene-C-N-C-N	55
6.3.1.1.1.1.9.	Fragment Arene-N-C-N-C	56
6.3.1.1.1.1.10.	Fragments Arene-C-N-C and N	61
6.3.1.1.1.1.11.	Fragments Arene-N-C-N and C	62
6.3.1.1.1.1.12.	Fragments Arene-N-C and N-C	64
6.3.1.1.1.1.13.	Fragments Arene-C and N-C-N (or N and C-N) ..	68
6.3.1.1.1.1.14.	Fragments Arene-N and C-N-C	69
6.3.1.1.1.1.15.	Fragments Arene and C-N-C-N	71
6.3.1.1.1.1.16.	Involving Rearrangements	72
6.3.1.1.1.2.	From Hetarenes	73
6.3.1.1.2.	By Ring Transformation	74
6.3.1.1.2.1.	From 2 <i>H</i> -3,1-Benzoxazine-2,4(1 <i>H</i>)-diones (Isatoic Anhydrides)	74
6.3.1.1.2.2.	From Sulfinamide Anhydride and Carboxamides or Thiocarboxamides	78
6.3.1.1.2.3.	From 2-Amino-3,1-benzoxazin-4-ones and 2-Amino-3,1-benzothiazin-4-ones	78
6.3.1.1.2.4.	From 3,1-Benzoxazin-4-ones and Ammonia	79
6.3.1.1.2.5.	From 3,1-Benzothiazin-4-ones and 3,1-Benzothiazine- 4-thiones with Ammonia or Hydroxylamine	80
6.3.1.1.2.6.	From 3,1-Benzoxazinium Perchlorates	80
6.3.1.1.2.7.	From 3-(Arylideneamino)-1,2,3-benzotriazin-4-ones ...	80
6.3.1.1.2.8.	From 2-Aminoquinolin-4-ol	81
6.3.1.1.2.9.	From Hexafluorocinnoline	81
6.3.1.1.2.10.	From Polyphenylated Phthalazines	81
6.3.1.1.2.11.	From 2,2,4-Trimethyl-1,2-dihydroquinoline Hydrochlorides and Guanidine-1-carbonitrile	82
6.3.1.1.3.	By Aromatization	82

6.3.1.1.3.1.	Of the Heterocyclic Ring	82
6.3.1.1.3.2.	Of the Carbocyclic Ring	90
6.3.1.1.4.	By Ring Contraction	91
6.3.1.1.4.1.	From Seven-Membered Heterocyclic Compounds	91
6.3.1.1.4.2.	From Eight-Membered Heterocyclic Compounds	94
6.3.1.1.5.	By Ring Expansion	95
6.3.1.1.5.1.	From Five-Membered Heterocyclic Compounds	95
6.3.1.1.6.	With Retention of the Ring System	98
6.3.1.1.6.1.	Oxidation	98
6.3.1.1.6.2.	Onium Salts	99
6.3.1.1.7.	By Removal of Substituents	102
6.3.1.1.7.1.	Heterofunctional Groups	102
6.3.1.1.7.1.1.	Halogens	102
6.3.1.1.7.1.2.	<i>O</i> -Functional Groups	102
6.3.1.1.7.1.3.	<i>S</i> -Functional Groups	105
6.3.1.1.7.1.4.	<i>N</i> -Functional Groups	106
6.3.1.1.7.2.	Carbofunctional Groups	107
6.3.1.1.8.	By Introduction of Substituents	109
6.3.1.1.8.1.	Heterofunctional Groups	109
6.3.1.1.8.1.1.	Halogens	109
6.3.1.1.8.1.2.	<i>O</i> -Functional Groups	110
6.3.1.1.8.1.3.	<i>S</i> -Functional Groups	111
6.3.1.1.8.1.4.	<i>N</i> -Functional Groups	112
6.3.1.1.8.2.	Carbofunctional Groups	115
6.3.1.1.8.3.	Deuterium	118
6.3.1.1.9.	By Exchange of Substituents	118
6.3.1.1.9.1.	Oxo Group Transformations	118
6.3.1.1.9.2.	Thioxo Group Transformations	123
6.3.1.1.9.3.	Benzenesulfonyl Group Transformations	125
6.3.1.1.9.4.	Alkoxy, Aryloxy, Alkylsulfanyl and Arylsulfanyl Group Transformations	126
6.3.1.1.9.5.	<i>N</i> -Functional Group Transformations	127
6.3.1.1.9.6.	Halogen Group Transformations	127
6.3.1.1.9.7.	Hydrolysis of Chloro-, Alkoxy-, and Alkylsulfanylquinazolines, Quinazolinethiones and Quinazolinamines	132
6.3.1.1.9.8.	Carbofunctional Group Transformations	133
6.3.1.1.10.	By Modification of Substituents	135
6.3.1.1.10.1.	Oxo and Thioxo Group Transformations	135
6.3.1.1.10.2.	Methyl Group Transformations	137
6.3.1.1.10.3.	Of 2-(Chloromethyl)quinazoline 3-Oxides	140
6.3.1.1.10.4.	Of Nitroquinazolines	141
6.3.1.1.10.5.	Of Alkoxyquinazolines	141
6.3.1.1.11.	By Annulation of Heterocycles to the Performed Ring System	142
6.3.1.1.12.	By Rearrangement	142
6.3.1.2.	Transformations	148
6.3.1.2.1.	Ring Opening with Retention of the Oxidation Level	148
6.3.1.2.2.	Oxidation Reactions	150
6.3.1.2.2.1.	Without Ring Opening	150
6.3.1.2.2.2.	With Ring Opening	151
6.3.1.2.3.	Reduction Reactions	152

	6.3.1.2.3.1. Without Ring Opening	152
	6.3.1.2.3.2. With Ring Opening	155
6.3.1.2.4.	Into Other Heterocycles	156
	6.3.1.2.4.1. With Retention of Ring Size	156
	6.3.1.2.4.2. With Ring Contraction	158
	6.3.1.2.4.3. With Ring Expansion	159
6.3.1.2.5.	Addition Reactions	160
	6.3.1.2.5.1. Of Heterofunctional Groups	160
	6.3.1.2.5.2. Of Carbofunctional Groups	162
	6.3.1.2.5.3. Cycloadditions	170
6.3.1.2.6.	Condensation Reactions	173
6.3.1.2.7.	Rearrangements	173
6.3.2.	Quinoxalines	193
	(U. URLEB)	
6.3.2.1.	Synthesis	196
6.3.2.1.1.	By Ring-Closure Reactions	196
	6.3.2.1.1.1. From 1,2-Difunctional Arenes	196
	6.3.2.1.1.2. From Monofunctional Arenes	211
	6.3.2.1.1.3. From 1,4-Benzoquinone Derivatives with Ethane- 1,2-diamine	212
6.3.2.1.2.	By Aromatization	212
	6.3.2.1.2.1. Oxidation of 1,2,3,4-Tetrahydroquinoxalines	212
	6.3.2.1.2.2. Oxidation of 1,2-Dihydroquinoxalines	214
	6.3.2.1.2.3. Oxidation of 3,4-Dihydroquinoxalin-2(1 <i>H</i>)-ones or 2,3-Dione Derivatives	214
6.3.2.1.3.	By Ring Contraction or Ring Enlargement	215
	6.3.2.1.3.1. By Ring Contraction of a 7-Membered Heterocycle	215
	6.3.2.1.3.2. By Ring Enlargement of a 5-Membered Heterocycle	216
6.3.2.1.4.	With Retention of the Ring System	221
	6.3.2.1.4.1. Oxidation with Formation of <i>N</i> -Oxides	221
	6.3.2.1.4.2. Synthesis of Onium Salts	223
	6.3.2.1.4.3. By Removal of Substituents (Exchange for Hydrogen) ..	225
	6.3.2.1.4.4. By Introduction of Substituents (Exchange of Hydrogen)	226
	6.3.2.1.4.5. By Exchange of Substituents	235
	6.3.2.1.4.5.1. Carbofunctional Groups	235
	6.3.2.1.4.5.2. Heterofunctional Groups	235
	6.3.2.1.4.6. By Modification of Substituents	244
	6.3.2.1.4.7. By Annulation to the Preformed Ring System	247
	6.3.2.1.4.8. By Rearrangement from Quinoxaline <i>N</i> -Oxides	248
6.3.2.2.	Transformations	249
6.3.2.2.1.	Oxidation Reactions	249
6.3.2.2.2.	Reduction Reactions	250
	6.3.2.2.2.1. Without Ring Opening	250
	6.3.2.2.2.2. With Ring Opening	252
6.3.2.2.3.	Into Other Heterocycles	252
6.3.2.2.4.	Addition Reactions	254
6.3.2.2.5.	Polymerization	256

6.3.3.	Phenazines	266
	(U. URLEB)	
6.3.3.1.	Synthesis	268
6.3.3.1.1.	By Ring-Closure Reactions	269
	6.3.3.1.1.1. From 1,2-Difunctional Arenes	269
	6.3.3.1.1.2. From <i>N</i> -Monofunctional Arenes	278
	6.3.3.1.1.3. From 1,2-Difunctional Hetarenes: Quinoxalines	280
6.3.3.1.2.	By Aromatization	281
6.3.3.1.3.	By Ring Enlargement of Benzofuroxans (the Beirut Reaction)	281
6.3.3.1.4.	With Retention of the Ring System	284
	6.3.3.1.4.1. Oxidation (Formation of <i>N</i> -Oxides)	284
	6.3.3.1.4.2. Synthesis of Onium Salts	285
	6.3.3.1.4.3. By Removal of Substituents (Exchange for Hydrogen) ..	286
	6.3.3.1.4.4. By Introduction of Substituents (Exchange of Hydrogen)	287
	6.3.3.1.4.5. By Exchange of Substituents	292
	6.3.3.1.4.6. By Modification of Substituents	294
	6.3.3.1.4.7. By Rearrangement	295
	6.3.3.1.4.8. Biosynthesis	295
6.3.3.2.	Transformations	296
6.3.3.2.1.	Oxidation Reactions with Ring Opening	296
6.3.3.2.2.	Reduction Reactions Without Ring Opening	296
6.3.3.2.3.	Conversion into Other Heterocycles	297
6.3.3.2.4.	Addition Reactions	298
6.3.3.2.5.	Rearrangements of Phenazine <i>N</i> -Oxides by Irradiation	299
7.	Bicyclic 6-Ring Systems Each with One to Two <i>N</i>-Atoms	304
7.1.	Purines	304
	(F. SEELA, N. RAMZAEVA and H. ROSEMEYER)	
7.1.1.	Synthesis	331
7.1.1.1.	By Ring-Closure Reactions	331
	7.1.1.1.1. From Acyclic Precursors	331
	7.1.1.1.2. From Pyrimidine-4,5-diamines	336
	7.1.1.1.2.1. Aminopurines	337
	7.1.1.1.2.2. Hydroxy- and Alkoxy purines	339
	7.1.1.1.2.3. Aminohydroxypurines	343
	7.1.1.1.2.4. Sulfanyl-, Aminosulfanyl- and Hydroxysulfanylpurines ..	345
	7.1.1.1.2.5. Halopurines	347
	7.1.1.1.2.6. <i>C</i> -Alkyl-, <i>C</i> -Aryl- and <i>C</i> -Carboxypurines	349
	7.1.1.1.2.7. <i>N</i> -Alkylpurines and Nucleosides	351
	7.1.1.1.3. From Other Disubstituted Pyrimidines	356
	7.1.1.1.4. From Imidazole Precursors	364
	7.1.1.1.4.1. 4(5)-Aminoimidazole-5(4)-carboxamides and Related Derivatives	364
	7.1.1.1.4.2. 4(5)-Aminoimidazole-5(4)-carbonitriles	371
	7.1.1.1.4.3. 4(5)-Aminoimidazole-5(4)-carboximidamides	375
	7.1.1.1.4.4. Other Imidazole Precursors	377
	7.1.1.1.4.5. Nucleosides	380
	7.1.1.1.4.5.1. AICA-Riboside and Related Compounds	380

	7.1.1.1.4.5.2. AICN-Riboside or Its 2'-Deoxyriboside	384
	7.1.1.1.4.5.3. Other Substrates	387
7.1.1.2.	By Ring Contraction and Ring Conversion	391
	7.1.1.2.1. Ring Contraction	391
	7.1.1.2.2. Purines Derived from Pyrimidine-Containing Heterocycles	392
7.1.1.3.	With Retention of the Ring System	395
7.1.1.3.1.	By Introduction of Substituents Using Oxidation	395
7.1.1.3.2.	By Removal of Substituents	398
7.1.1.3.3.	By Introduction of Substituents (Exchange of Hydrogen)	403
	7.1.1.3.3.1. Deuterated and Tritiated Purines	403
	7.1.1.3.3.2. By Halogenation	404
	7.1.1.3.3.3. By Hydroxylation	410
	7.1.1.3.3.4. By Thiation	410
	7.1.1.3.3.5. By Nitration	410
	7.1.1.3.3.6. By Animation	412
	7.1.1.3.3.7. By C-Alkylation	414
	7.1.1.3.3.8. By N-Alkylation	418
	7.1.1.3.3.9. By N-Glycosylation	430
	7.1.1.3.3.10. Acyclonucleosides	448
	7.1.1.3.3.11. Carbocyclic Nucleosides	449
	7.1.1.3.3.12. Bridged Purines	450
	7.1.1.3.3.13. Functionalized Purines and Polymeric Aggregates Thereof	452
7.1.1.3.4.	By Exchange of a Substituent by Another	462
	7.1.1.3.4.1. Aminopurines	462
	7.1.1.3.4.1.1. From Halopurines	462
	7.1.1.3.4.1.2. From Sulfanyl- and Hydroxypurines and by Exchange of Amino Groups in Aminopurines	471
	7.1.1.3.4.2. Hydroxypurines	478
	7.1.1.3.4.2.1. From Halopurines	478
	7.1.1.3.4.2.2. From Alkoxypurines	483
	7.1.1.3.4.2.3. From (Alkylsulfanyl)purines	484
	7.1.1.3.4.2.4. From Aminopurines	486
	7.1.1.3.4.3. Alkoxypurines	491
	7.1.1.3.4.4. Sulfanylpurines	497
	7.1.1.3.4.5. Halopurines	505
	7.1.1.3.4.5.1. By Halogen Exchange	505
	7.1.1.3.4.5.2. From Hydroxypurines	506
	7.1.1.3.4.5.3. From Sulfanylpurines	510
	7.1.1.3.4.5.4. From Aminopurines	514
	7.1.1.3.4.6. C-Alkyl-, C-Alkenyl-, and C-Alkynylpurines	519
7.1.1.3.5.	By Rearrangement of Substituents	527
7.1.1.3.6.	By Modification of Substituents	528
7.1.1.3.7.	Fused Purines	532
7.1.2.	Transformations	540
7.1.2.1.	Oxidation	540
7.1.2.2.	Reduction	541
	7.1.2.2.1. Purines Reduced in the Pyrimidine Ring	541
	7.1.2.2.2. Purines Reduced in the Imidazole Ring	542
7.1.2.3.	Addition Reactions to Purine Double Bonds	543

7.1.2.4.	Photochemical Stability of Purines	543
7.1.3.	Metal Complexes of Purines, Purine Nucleosides, Nucleotides, and Nucleic Acids	544
	Bibliography to Vol. E 9b/Part 2	547